Vendor Advice for RBM and RBQM Technology Buyers
IDC MarketScape has listed Cyntegrity as one of the top 8 RBQM vendors in its “Worldwide Life Science R&D Risk-Based Monitoring Solutions 2022 Vendor Assessment” study.
This IDC study focuses on a combination of Risk-based Monitoring (RBM) technology and consulting solutions. IDC MarketScape provides a qualitative and quantitative assessment based on criteria that should be important to life science companies when considering the selection of a strategic RBM solution provider. The report will help guide strategic, operational, and tactical transformation issues within the RBM and Risk-based Quality Management (RBQM) space and technology platforms and build capabilities. This is the first time an IDC MarketScape assessment of RBM solutions for life science R&D has been performed.
Dr. Nimita Limaye, research VP, Life Science R&D Strategy and Technology at IDC, noted, “The differentiator for great enterprises is not the amount of data they have but the intelligence that they extract from it to minimize study risk, enhance data quality, and drive patient safety. The future of intelligence for clinical trials encompasses effectively leveraging an RBQM strategy, deeply embedding a QbD approach within the organization’s DNA, building a quality-centric culture, and optimizing the use of technology solutions to develop an agile, predictive, prescriptive, and a proactive strategy to managing risks.”
Among other aspects, the comprehensive vendor assessment provides insight into Cyntegrity’s strengths and challenges and advises which cases Cyntegrity’s RB(Q)M solutions are best suited to. Learn more…
